INTRODUCTION
The T H 17 cell lineage represents an effector T-cell subset particularly enriched in the small intestinal lamina propria, where it protects the host from bacterial infections. 1 However, when their regulation fails, T H 17 cells also have the potential of becoming key drivers of several autoimmune disorders like multiple sclerosis 2 and inflammatory bowel disease. 3 Given that T H 17 cells have emerged as heterogeneous and flexible cells, highlighting how cell plasticity plays a central role in keeping the balance between pathogenicity and tolerance, 4 it is of crucial importance to understand how the diverse functions of this cell subset are regulated.
In vivo animal models of tolerance induction, such as anti-CD3 treatment, have identified the small intestine (SI) as a major regulatory organ not only for local, but also for systemic immune function. 5 Anti-CD3 treatment leads to two well characterized and distinct phases in the subsequent immune response. The first phase (day 1) results in a systemic immune stimulation provoked by a strong cytokine release that results in flu-like symptoms and in the disappearance of T cells from the periphery, 6 together with T-cell dependent small intestinal injury. 7 Nevertheless, the cytokine release is only transient and self-limiting and it resolves with the complete restoration of the intestinal tissue and systemic homeostasis 8 by the fourth or fifth day of treatment, corresponding to the second phase, the resolution of inflammation. Resolution of inflammation leads to active systemic immunological tolerance mediated by regulatory T cells. In the anti-CD3 treatment model of tolerance induction, as well as in infection models such as sepsis and during influenza A viral infection (H1N1), proinflammatory T H 17 cells are recruited to the SI via the CCR6/ CCL20 axis. 5 In the SI, T H 17 cells transdifferentiate into regulatory T cells, which are able to effectively suppress proliferation of effector T cells both in vitro and in vivo.
The local tissue response upon injury and the tissue-specific accumulation of T H 17 cells makes anti-CD3 treatment a good model to study T H 17 cells in inflamed tissue, as well as the subsequent modulation of the ongoing T-cell response. In consideration of evidence pointing to the intestine as a crucial immune organ, where tolerance is strictly and efficiently maintained to avoid unwanted immune responses to self-, dietary, or commensal antigens, 11, 12 it is of great interest to comprehend tissue-specific mechanisms, by which the gut is capable of inducing tolerance in T H 17 cells.
Interleukin-33 (IL-33) is a member of the IL-1 cytokine family, 13 mainly expressed by endothelial and epithelial cells at mucosal interfaces 14 and known to function as an alarmin, a molecule rapidly indicating tissue damage upon injury or infection. 15 Although IL-33 has been linked to various inflammatory processes and autoimmune diseases, 16 recent studies have described the role of IL-33 in tissue regulation and repair, especially in the intestine. 17 IL-33 signals through the ST2 receptor, expressed by multiple non-hematopoietic and hematopoietic cells. The wide distribution of ST2 and the interplay between its constitutive and induced expression point to a key role of the IL-33/ST2 axis in both inflammation and homeostasis, affecting innate as well as adaptive immune responses. A deeper knowledge of the tissue-and cell-specific mechanisms by which the IL-33/ST2 axis governs both processes in the intestine remains an important area for exploration.
In this study, we found that epithelial cells in the proximal part of the SI are the main source of IL-33 upon inflammation. We describe for the first time ST2 expression in T H 17 cells in vivo and we show that in both mouse and human T H 17 cells, IL-33 promotes a reduced expression of pro-inflammatory genes, including Tbx21, Ifng, and Csf2, and an increase in Il10, an anti-inflammatory cytokine that has non-redundant roles in Figure 1 IL-33 is upregulated in intestinal epithelial cells (IEC) in the proximal part of the small intestine upon CD3-specific antibody injection. C57BL/6 (a-d) or IL17A-eGFPxFoxp3-mRFP reporter (e-f) mice were injected i.p. with anti-CD3 at days 1, 3, and 5. Four hours after each injection, the different parts of the intestine were isolated, as well as the spleen and mesenteric lymph nodes (MLN) (control tissues). limiting inflammation in the intestine 18 and in controlling previously committed pathogenic T H 17 cells. 5, 9, 19 Figure S1a) . Il33 mRNA levels were upregulated in the CD45
À -cell fraction of treated animals compared with CD45 À cells from untreated mice, confirming the transcriptome data (Supplementary Figure S1b) . To further decipher the specific cellular source of IL-33 in the SI, we performed immunofluorescence staining of tissue sections. Extensive IL-33 staining was detected in EpCAM þ epithelial cells located in the apical part of the villi in the duodenum of treated mice (Figure 1a) . By contrast, IL-33 expression in steady state was only detected in isolated PECAM þ endothelial cells located in the crypt region (Figure 1a) . Histological analysis of peripheral lymphoid tissues revealed only few cells expressing IL-33 in the spleen and mesenteric lymph nodes and no differences were observed upon anti-CD3 treatment (Figure 1b) Figure S1c) . In line with our previous findings, Il33 levels were 450-fold upregulated at day 1, decreasing rapidly afterwards. Il33 was mainly restricted to the duodenum and, to a lesser extent, to the jejunum ( Figure 1c) . We confirmed the upregulation of Il33 in the proximal part of the SI from anti-CD3-treated mice by immunofluorescence microscopy. Notably, IL-33 decreased toward the distal parts in a gradient-like fashion, with only marginal expression in the ileum and non-detectable expression in the colon (Figure 1d ). To explore in depth the kinetics of Il33 specifically in the duodenum, where its highest levels were observed, we analyzed the tissue at 4 and 24 h after each injection. Indeed, a peak of Il33 was observed 4 h after the first injection (day 1), after which the levels decreased to a value sixfold less (Figure 1e) . However, the transcript was upregulated within 4 h after every additional injection, but only reaching a twofold increase. The acute and time-limited expression of Il33 in the inflamed SI emphasized its role as an alarmin. The kinetics was confirmed by immunofluorescence staining of the duodenum (Figure 1f) , where histological analysis also showed that, upon anti-CD3 treatment, upregulation of IEC-derived IL-33 (green) was concurrent with the recruitment of T H 17 cells (red) in the lamina propria (LP). Importantly, anatomical localization of IL-33 corresponded to distinct parts of the intestine where T H 17 cells accumulate. 5 On the basis of these data, we aimed to determine whether accumulating SI T H 17 cells may respond to IL-33.
T H 17 cells show inducible ST2 expression IL-33 mediates its function via ST2, a plasma membrane receptor that has been described to be expressed in various T-cell subsets including T H 2, 20 T H 1, 21 and Tregs. 22 However, it is not known whether T H 17 cells express ST2. Therefore, we analyzed ST2 expression by flow cytometry in the spleen and the SI of IL17A-eGFPxFoxp3-mRFP double reporter mice at steady state and during anti-CD3 treatment (gating strategies and control staining for ST2 shown in Supplementary Figure  S2a Splenic T H 17 cells express CCR6, a chemokine receptor known for playing a role on directing T H 17 cells toward the SI, where high amounts of CCL20, the ligand of CCR6, are released during anti-CD3 treatment. 5 Indeed, B90% of splenic T H 17 cells expressed CCR6 during the resolution of inflammation (day 5) and, interestingly, ST2 expression in this subset was largely restricted to CCR6-expressing cells, while ST2 expression in Tregs was mainly restricted to the CCR6 À population ( Figure 2d ). We also compared the expression of the gut homing receptor CCR6 between ST2 À and ST2 þ T H 17 cells in the spleen and the SI during anti-CD3 treatment. While ST2 þ T H 17 cells expressed high levels of CCR6 (B60%) in both tissues during resolution of inflammation, ST2
À T H 17 expressed high levels of CCR6 only in the spleen, but reduced levels (B15%) in the SI (Supplementary Figure S3 ).
Although frequencies of T H 17 cells were higher in the intestinal ST2
þ T-cell pool than in the spleen, the analysis of the mean fluorescence intensity of ST2 in T H 17 cells revealed a reduction in the SI, indicating that T H 17 in this tissue expressed reduced levels of ST2 at the single cell level, compared with the spleen (Figure 2e ). Together, these data demonstrate an inducible expression of ST2 in T H 17 cells upon anti-CD3 treatment.
Absence of ST2-mediated signaling favors the expansion of pro-inflammatory T H 17 cells in the SI upon inflammation
In light of the finding that T H 17 cells express ST2 in vivo, we next aimed to assess the role that the IL-33/ST2 signaling pathway plays in these cells. For that, T H 17 responses upon anti-CD3 treatment were compared between St2 À / À mice and control littermates ( Figure 3a ; gating strategies shown in Supplementary Figure S2a ). Because we found the strongest upregulation of IL-33 during the acute inflammation phase (day 1) (Figure 1c and f), we expected the greatest difference between St2 À / À and control mice at this time point. In the absence of ST2 signaling, frequencies of RORgt þ , Foxp3 þ , and RORgt þ /Foxp3 þ cells were significantly increased in the spleen, while frequencies of cytokine-expressing T cells did not change between the two cohorts ( Figure 3b ). We observed a selective enrichment in the SI of St2 À / À mice, both in frequencies and total numbers, of RORgt-expressing cells (Figure 3c and d) . By contrast, frequencies of intestinal Foxp3-expressing cells and Foxp3/RORgt-double expressing cells were unaffected by ST2 deficiency (Figure 3c ). Interestingly, elevated frequencies and total numbers of IL-17A þ T cells were also found in the SI in the absence of St2, as well as higher frequencies of IFN-g/IL-17A-and TNF-a/IL-17A-double expressing cells (Figure 3c and d), suggesting that St2 deficiency specifically enhances the pro-inflammatory capacity of T H 17 cells in our settings. However, no significant differences were observed in IFN-g or TNF-a single production by T cells (Figure 3c ). The hypothesis of an exacerbated T H 17 pro-inflammatory response in the absence of ST2 signaling was further supported by the gene expression analysis of in vitro differentiated St2 À / À T H 17 cells, which showed enhanced expression of Rorc, Il17a, and Ifng when compared with WT T H 17 cells (Figure 3e) .
The analysis at day 3 after treatment showed, as expected, milder differences between groups (Supplementary Figure  S4a) . At day 5, no differences were detected (Supplementary Figure S4b) . We also compared T-cell populations under homeostatic conditions and St2 À / À mice and control littermates showed similar levels of T-cell-derived cytokines in the spleen and the SI (Supplementary Figure S4c) , in line with the absence of any immune phenotype observed in these mice and confirming what has already been reported for the St2 À / À mouse strain. 23 Hence, the differences observed in the SI T H 17 population in St2 À / À mice at day 1 were induced by the treatment, suggesting a link between IL-33/ST2 axis and the ongoing acute inflammatory response. Together, our results show that the IL-33/ST2 axis specifically limits the expansion of pathogenic T H 17 cells in the SI upon inflammation. The exacerbated intestinal T H 17 response observed in St2 À / À mice during the acute inflammatory phase also led to clinical manifestations. Mice lacking St2 showed greater body weight loss upon anti-CD3 treatment (Supplementary Figure S5a) , as well as a higher inflammation score in the duodenum (Supplementary Figure S5b) . This was associated with an enhanced inflammatory cytokine milieu, as depicted by an upregulation of the pro-inflammatory genes Il17a, Ifng, and Tnf, together with a downregulation of the anti-inflammatory gene Il10 (Supplementary Figure S5c) .
It has already been reported by us that during resolution of inflammation, T H 17 cells located in the LP display an immunosuppressive phenotype characterized by their ability to produce IL-10. Consequently, they are able to effectively suppress the proliferation of naive T cells in vitro and ameliorate the clinical course of experimental autoimmune encephalomyelitis (EAE), demonstrating their in vivo regulatory function. 5, 9, 10 To analyze whether ST2 signaling in T H 17 cells may also have an impact on IL-10 induction, we followed two different strategies. On the one hand, we administered a blocking antibody against ST2 in vivo 24,25 prior to anti-CD3 injections. On the other hand, we used IL-10-GFP reporter mice with genetically deleted St2 (IL-10-GFP.T1ST2KO mice). In both cases, we analyzed 
ARTICLES
MucosalImmunology | VOLUME 10 NUMBER 6 | NOVEMBER 2017
intestinal T H 17 cells during resolution of the inflammation, the phase in which the highest levels of T-cell-derived IL-10 were expected (Figure 4a) . The frequency of intestinal RORgt þ T cells was found increased in the anti-ST2-treated group compared with the group treated with control antibodies (Figure 4b) . These results were similar to our observations in the IL-10-GFP.T1ST2KO mice (Figure 4c) , pointing to an effective in vivo blockade of the receptor. Interestingly, the intestinal T H 17 population in the anti-ST2-treated group not only showed increased frequencies of IL-17A producers, but also reduced frequencies of IL-10 þ T H 17 cells (Figure 4d) . Analysis of IL-10-GFP.T1ST2KO mice showed similar results (Figure 4e) , suggesting that absence of ST2 signaling leads to a reduction of IL-10 secretion by T H 17 cells, supporting their proinflammatory phenotype. As expected, the maximum of IL-10 production was found in T H 17 cells treated with IL-27, a cytokine known to strongly induce IL-10. 28 Notably, IL-33 also dampened the production of the pro-inflammatory cytokine granulocyte macrophagecolony stimulating factor (GM-CSF) by human T H 17 cells (Figure 5d ). Together, these data indicate that IL-33 is capable of inducing changes in the genetic profile of murine and human T H 17 cells in favor of a reduced pathogenic phenotype and promotes the expression of the anti-inflammatory cytokine IL-10. This was also supported by our finding that Ahr, 10 Ikzf3, Jun, and Irf4, 29 all known to be IL-10-related genes, were found to be upregulated by IL-33 in T H 17 cells, together with Il10 (Figure 5e ). Expression of Ahr was also found to positively correlate with Il10 expression in T H 17 cell cultures (Supplementary Figure S6) , suggesting that the transcription factor Ahr may be involved in the induction of Il10 downstream of IL-33/ST2 signaling. Although Maf is a reported inducer of Il10 in T H 17 cells, 30 it was not upregulated upon IL-33 signaling (Figure 5e ). Nevertheless, expression of Maf was found to correlate with Il10 expression in T H 17 cell cultures (Supplementary Figure S6) , indicating a link between both transcripts, but not with IL-33.
The hypothesized role of IL-33 in shifting the phenotype of pro-inflammatory T H 17 cells toward an anti-inflammatory subset producing IL-10 was further supported by the gene expression profile observed after administration of IL-33 to ex vivo sorted splenic IL-17A-EGFP þ RFP À (T H 17) cells (Figure 6a) . T H 17 cells downregulated Rorc upon IL-33 administration, while Foxp3 levels remained unchanged in this cell subset (Figure 6b) . On the contrary, Il10 expression was induced by IL-33 in a dose-dependent manner in T H 17 cells, while its levels were only marginally, non-significantly increased in Tregs. Furthermore, the expression of Ifng was efficiently downregulated by IL-33 in T H 17 cells even at low doses (Figure 6b) . Surprisingly, although fresh ex vivo sorted T H 17 cells expressed Il17a (control), the transcript could not be detected upon 24 h of culture without any TCR activator, independently of the addition of IL-33 to the culture medium. Finally, we sought to compare the in vitro suppressive capacity of IL-33-stimulated T H 17 cells with untreated T H 17 cells and professional Tregs. As expected, professional Tregs inhibited T-cell proliferation to the greatest extent. Nevertheless, addition of IL-33 significantly enhanced murine T H 17 suppressor functions (Figure 6c and d) . Collectively, our data indicate that the exacerbated T H 17 response observed in vivo in St2 À / À mice upon inflammation, as well as the reduced levels of T H 17-derived IL10 observed in anti-ST2-treated mice are due, at least in part, to IL-33 signaling in T H 17 cells. This leads to a Foxp3-independent increase in Il10 and a decrease in Rorc and Ifng expression, promoting the acquisition of a regulatory phenotype.
DISCUSSION
It has recently been demonstrated by us that the SI controls potentially inflammatory T H 17 cells to avoid exacerbated immune responses. 5 However, the underlying mechanisms governing this process are only partially understood. 19) and TGF-b (ref. 10) are two key immune-regulatory mediators known to limit T H 17 cell pathogenicity, but both cytokines are mostly produced by myeloid cells and are not specifically induced in the SI. Here we identified IL-33 as a local factor produced by epithelial cells in the SI, in control of the T H 17 lineage. A proper understanding of the tissue-derived, local factors controlling T H 17 cells may help fighting chronic inflammatory processes and autoimmune diseases driven by this T-cell subset, such as multiple sclerosis, 2 rheumatoid arthritis, 31 and inflammatory bowel disease. 3 Using the anti-CD3 model, we describe here for the first time ST2 expression in T H 17 cells in vivo and we show that the ST2/IL-33 axis can induce the conversion of T H 17 cells from an inflammatory phenotype to a functional suppressive subset co-producing IL-10. In recent years, the IL-33/ST2 axis has emerged as a key modulator of inflammation in epithelial tissues, 32 particularly in the gut mucosa. In this study, we show that IECs are the main source of IL-33 upon inflammation. Although IECs are CD3 À and therefore cannot be directly activated by CD3-specific antibodies to release IL-33, several studies have shown that anti-CD3 treatment activates CD3 þ intestinal intraepithelial lymphocytes, leading to the induction of cytotoxic pathways and consequently to tissue damage. [33] [34] [35] [36] [37] IL-33 is released by epithelial cells upon tissue damage and functions as an alarmin, alerting the immune system to mount an appropriate response. 14, 38, 39 Results from our group also suggest this indirect mechanism mediated by intraepithelial lymphocytes, by which anti-CD3 administration leads to release of IECderived IL-33 (data not shown). Our results show a rapid and strong IL-33 response in the proximal part of the SI, coinciding with the site of local inflammation caused transiently by anti-CD3 treatment. We found that the induction of IL-33 occurred in a gradient-like fashion along the intestine, from proximal to distal, similar to the expression of CCL20 and therefore coinciding with the spatial distribution of T H 17 cells in the gut. 5 In contrast, IL-33 expression upon treatment in the spleen remains at levels comparable to steady state. We found ST2 21 and in contraposition to the constitutive and abundant expression of ST2 shown by T H 2 cells and Tregs. 40 About 90% of splenic ST2
þ T H 17 cells co-express CCR6, a receptor known to direct these cells particularly to the proximal part of the SI, the region showing the strongest upregulation of the CCR6-ligand CCL20.
5
The differential expression of CCR6 in the intestinal ST2 þ (B50%) and ST2 À (B15%) T H 17 population might also indicate that the former represent newly accumulating T H 17 cells, as CCR6 is being downregulated in T H 17 cells after their recruitment to the gut. 5 Our findings indicate a spatial separation of ST2 induction in the spleen and the provision of IL-33 by the gut epithelium, which may be a mechanism to fine-tune the effects of IL-33 on T H 17 cells.
It has recently been published that ST2 deficiency led to exacerbated colitis due to deficient iTreg differentiation 22 and T cells driving colitis are known to express high amounts of IL-17A and the pro-inflammatory cytokines IFN-g, TNF-a, and GM-CSF. 3, [41] [42] [43] We did find increased Il17a, Ifng, and Tnf levels in the duodenum, as well as decreased levels of the antiinflammatory mediator Il10, in association with a higher degree of inflammation in the St2 À / À mice. Remarkably, ST2 deficiency also led to a specific increase both in frequencies and absolute numbers of T H 17 cells (RORgt þ T cells and IL-17A þ T cells) in the SI upon inflammation. In addition, intestinal T H 17 cells showed a greater pathogenic phenotype, featured by increased frequencies of both IL-17A þ IFN-g þ and IL-17A
þ TNF-a þ T cells. We observed equivalent frequencies of Foxp3-expressing cells in St2 À / À and WT mice in the SI upon inflammation. However, further analysis on the functionality of Tregs would be needed to exclude any contribution from these regulatory cells on the exacerbated T H 17 response found in the absence of ST2. On the one hand, we are aware that the anti-CD3 treatment is well suited to study the plasticity of T H 17 responses, but it does not reflect the full complexity of an inflammatory response in the gut, as it occurs during chronic inflammation. This may also explain why the differences observed between St2 À / À and WT mice in histopathology are rather mild. On the other hand, IL-10 is an anti-inflammatory cytokine that can be induced in T H 17 cells independently of Foxp3 and that confers these cells the intrinsic ability to exert regulatory functions. 19 The fact that genetic deletion of St2 and blocking of ST2 in vivo resulted, both, in a decreased LP IL-10 þ T H 17 population suggests a clear link between ST2 signaling and the secretion of the anti-inflammatory cytokine IL-10 by T H 17 cells. Taken together, our study complements the findings of other groups by extending the role of IL-33 beyond the induction and maintenance of Tregs in the colon 22 and visceral adipose tissue 44 to the conversion of pro-inflammatory into regulatory T H 17 cells in the SI.
IL-33 stimulation of ex vivo sorted T H 17 cells indeed led to changes in the expression levels of key genes modeling T H 17 functionality. Rorc was downregulated, although Foxp3 expression did not change in this subset, indicating that IL-33 limits T H 17 cells differentiation ex vivo, similarly to what we observed in vivo in St2 À / À mice. We also observed a reduction in Ifng, while Il10 expression was significantly increased, in a dosedependent manner, upon IL-33 stimulation. Surprisingly, Il17a expression could only be quantified in fresh ex vivo sorted T H 17 cells. In line with the ex vivo data, in vitro T H 17 cell cultures responded to IL-33 stimulation by downregulating proinflammatory genes such as Tbx21, Ifng, and Csf2, as well as upregulating Il10. Induction of IL-10 by the IL-33/ST2 axis in T H 17 cells was concurrent with the induction of a combination of transcription factors known to mediate IL-10 production in T cells. Among the transcripts positively regulated upon IL-33 stimulation together with Il10 were Ahr, Ikzf3, Irf4, and Jun. Moreover, Ahr expression correlated with the expression of Il10 in the cultures analyzed and it has already been shown to mediate T H 17 cell plasticity, to enhance IL-10 production and to be involved in the conversion of T H 17 into regulatory T cells. 10 Further experiments will be required to elucidate the role of Ahr in relation to the IL-33/ST2 axis. On a functional level, mouse T H 17 cells stimulated with IL-33 were able to suppress the proliferation of responder T cells in vitro, suggesting the acquisition of a regulatory phenotype. Importantly, in human T H 17 cells, in vitro IL-33 stimulation promoted an increase in IL-10 production, downregulation of TBX21 expression and reduction of GM-CSF secretion. GM-CSF has been shown to be a key cytokine for T-helper cells involved in chronic immune disorders, as GM-CSFproducing T cells exert a pathogenic role in the inflamed brain of multiple sclerosis patients. 45 Although our in vitro data demonstrate a role for the IL-33/ST2 axis in dampening T H 17 pathogenicity, we would like to emphasize that we cannot rule out a contribution of other ST2-expressing immune subsets, such as Tregs, Th2, and ILC2 (ref. 46) to the effects that we observe in vivo. Further experiments using inducible ST2 knockout systems will be required to address this question.
In summary, our results extend the spectrum of functions of the alarmin IL-33, highlight once more the role of the gut as an organ with systemic immune-regulatory functions and mechanistically explain the conversion of inflammatory into regulatory T H 17 cells occurring in the SI. A better knowledge of these tissue-derived, local factors in control of inflammatory and regulatory T cells might open the door for targeted immune modulation in the treatment of chronic inflammation and autoimmune diseases.
METHODS
Mice. Wild-type C57BL/6 and congenic B6.SJL-Cd45.1 mice were purchased from Charles River. St2 À / À mice, 23 IL17A-eGFPxFoxp3-mRFP reporter mice, 5 and IL-10-GFP reporter mice 47 on a C57BL/6 background were bred and housed under specific pathogen-free conditions in the animal facility of the Charité. For some experiments, IL-10-GFP reporter mice were crossed onto St2 À / À mice (IL-10-GFP.T1ST2KO). Mice were age-and sex-matched and 8-12 weeks old when used in experiments. Protocols for animal experiments were approved in accordance with institutional, state, and federal guidelines (Landesamt Für Gesundheit und Soziales, Berlin, Germany).
In vivo T-cell stimulation and intestinal lymphocyte isolation. Mice were injected with anti-CD3 antibodies (20 mg, clone 145-2C11, DRFZ) i.p. 1-3 times at an interval of 2 days between injections and were killed 4 h (or 24 h, where indicated) after the final injection. For the controls, isotype control or PBS was injected. Intestinal lymphocytes were isolated as previously described with minor modifications. 5 In brief, SIs were removed, opened longitudinally and then were cut into strips 1 cm in length. Tissues were washed twice in PBS and incubated with Hank's buffered saline (5% FCS) in the presence of 2 mM of EDTA at 37 1C for 30 min on a shaker. Afterwards, tissues were incubated with complete RPMI medium supplemented with 100 U ml À 1 of collagenase type IV (Sigma, Steinheim, Germany) at 37 1C for 30-40 min on a shaker. All released cells were loaded onto a Percoll gradient and centrifuged. The cells between 40 and 100% Percoll were collected and used as intestinal lymphocytes.
In vivo blocking of ST2. IL-10-GFP reporter mice (VertX, Jaxmice, Bar Harbor, ME) were injected with anti-ST2 antibodies (50 mg, clone DIH4, Biolegend, Fell, Germany) or isotype control antibodies (rat IgG1, clone RTK2071, Biolegend) i.p. 2 times (according to refs 24,25) 30 min prior to anti-CD3 injection and were killed after the second injection. Intestinal lymphocytes were isolated as described above.
Immunofluorescence microscopy. Small intestines and spleen were removed from wild type or IL17A-EGFPxFoxp3-RFP reporter mice before and after CD3-specific antibody treatment in vivo. Tissues were fixed in 1% paraformaldehyde at 4 1C over night. Subsequently paraformaldehyde was replaced with 30% sucrose solution and incubated at 4 1C for 6-8 h. After that, samples were washed and placed in oct-filled cryomolds. For freezing, the cryomolds were placed in chamber filled with 2-methylbutane, which was subsequently placed in dry ice submerged with ethanol. After freezing, the samples were stored at À 80 1C. Cryosections were cut at 7 mm on a Leica CM1850 freezing microtome, transfered onto Superfrost Plus Gold slides (Fisher Scientific, Jena, Germany) and air dried. For immunohistological staining, sections were surrounded with a PAP pen (Zymed Laboratories, Jena, Germany) and submerged with PBS for 20 min. After that, sections were blocked for 20 min at room temperature with 10% rat serum in PBS. For immunofluorescent staining, antibodies were diluted in staining buffer (PBS, 3% BSA, 0.1% Tween, and 0.01%Triton) and incubated at room temperature for 60 min. The following antibodies were used for staining: anti-CD11c-Alexa Fluor 647 (N418, produced in house), anti-PECAM-Alexa Fluor 647 (MEC13.3, Biolegend), anti-IL-33-Alexa Fluor 594 (polyclonal goat IgG, R&D systems, Minneapolis, MN), anti-EpCAM-Alexa-488 (G8.8, Biolegend), Hoechst 33342 or DAPI (as indicated), and anti-GFPAlexa-488 (polyclonal, Goat IgG, Rockland, Boyertown, PA). Nuclear stains were added after washing once with PBS for 5 min and incubated for 10 min at room temerature. After staining, samples were washed three times by immersing in PBS for 5 min and mounted with ProLong gold mounting medium (Life Technologies, Waltham, MA). Sections were analyzed by confocal microscopy using a Zeiss LSM 710 microscope with Â 20/0.5 NA (air) objective at room temperature.
Histopathology. SIs were removed and fixed immediately in 10% neutral-buffered formalin in PBS for 424 h, embedded in paraffin and cut into 5-7 mm sections. The sections were deparaffinized and stained with hematoxylin and eosin to determine histological changes.
Antibodies and intracellular cytokine staining. Anti-CD44-APC, anti-CD62L-FITC, anti-CD4-APC-Cy7, and anti-CD25-PE were purchased from eBioscience and used for FACS sorting of mouse naive T-cell populations. To stain T cells from spleen and SI of IL17A-EGFPxFoxp3-RFP or IL-10-GFP reporter mice before and after CD3-specific antibody treatment, cell suspensions were obtained as described above and first incubated with erythrocyte lysis buffer (ACK), followed by an FC-blocking antibody (anti CD16/32, clone 2.4G2, generated in the DRFZ) to prevent non-specific binding. Single cell suspensions were stained with anti-CD45-Pacific Blue, anti-CD4-BV785, anti-TCRb-PE-Cy7 anti-CCR6-BV605, live-dead-eF780 (all from eBioscience, Jena, Germany) and anti-ST2 (DJ8, MD Biosciences) conjugated to digoxigenin (produced in the DRFZ). A second incubation with anti-DIG-PE, followed by two rounds of Faser kit-PE (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturers' protocol was performed. For cytokine detection, cells were restimulated with PMA (5 ng ml À 1 ) and Ionomycin (500 ng ml À 1 ) for 5 h with addition of Brefeldin A and Monensin (5 mg ml À 1 ) at 30 min, followed by fixation in 2% formaldehyde. Intracellular staining was performed in PBS/0.2% BSA containing 0.05% saponin with anti-IL-17A-FITC (TC11-18H10.1, Biolegend) or anti-IL-17A-APC (TC11-18H10.1, Biolegend) anti-IFN-g-Pacific Blue (XMG1.2, eBioscience) and anti-TNFa-PerCP (MP6-XT22, Biolegend). T-bet, Roryt, c-maf, and Foxp3 protein amounts were analyzed using the Foxp3 staining buffer set (eBioscience) according to the manufacturer's instructions. Briefly, cells were stained with antibodies against CD4 (RM4-5, PE-Cy7, eBioscience) and CD45.2 (104, APC, BD, Heidelberg, Germany) and then fixed with fixation/ permeabilization buffer (BD), followed by intracellular staining with Pacific Blue-conjugated anti-T-bet (4B10, Biolegend), PE-conjugated anti-Rorgt (104 or Q31-378 BD) and FITC-conjugated anti-FoxP3 (FJK-16 s, eBioscience) in permeabilization buffer. The following antibodies were used for FACS sorting of human peripheral blood mononuclear cells: anti-CCR6-PE (11A9) or biotinylated anti-CCR6 followed by streptavidin-Pacific Blue, anti-CCR4-PE (1G1), anti-CXCR3-APC (1C6/CXCR3), anti-CD45RA-FITC (HI100, all from BD Biosciences), anti-CD25-FITC (B1.49.9), anti-CD8-PC5 (B9.11, both from Immunotech, Quebec, Canada). with plate bound anti-CD3 (3 mg ml À 1 ; 145-2C11; Miltenyi) and soluble anti-CD28 (2 mg ml À 1 ; 37.51; Miltenyi) in RPMI Media 1640 (Invitrogen, Jena, Germany) supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 2 mM L-glutamine, 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin, 5 mM 2-b-mercaptoethanol under T H 17 conditions: TGF-b (2 ng ml À 1 ; R&D systems) and IL-6 (25 ng ml À 1 ; R&D systems). Neutralizing anti-IFN-g (XMG1.2; own produced) and anti-IL-4 (11B11; produced in house) were each used at 5 mg ml À 1 . Where indicated, IL-33 (20 ng ml À 1 ; R&D) was added to the culture. For the human cultures, healthy leukapheresis blood and buffy coats were randomly obtained from the Charité Blood Bank and Deutsches Rotes Kreuz (DRK). Ethics approval was obtained from the Institutional
